中华妇产科杂志
中華婦產科雜誌
중화부산과잡지
CHINESE JOUNAL OF OBSTETRICS AND GYNECOLOGY
2009年
11期
856-860
,共5页
李奇灵%王运萍%高尚风%马军%冯彩霞%王月玲
李奇靈%王運萍%高尚風%馬軍%馮綵霞%王月玲
리기령%왕운평%고상풍%마군%풍채하%왕월령
卵巢肿瘤%癌症疫苗%免疫疗法%过继%淋巴细胞减少%疾病模型%动物
卵巢腫瘤%癌癥疫苗%免疫療法%過繼%淋巴細胞減少%疾病模型%動物
란소종류%암증역묘%면역요법%과계%림파세포감소%질병모형%동물
Ovarian neoplasms%Cancer vaccines%Immunotherapy%adoptive%Lymphopenia%Disease models%animal
目的 探索化疗后淋巴细胞减少期行免疫重建及应用GM-CSF基因修饰的卵巢上皮性癌(卵巢癌)肿瘤疫苗过继免疫治疗方案增强抗肿瘤免疫反应的机制及效果.方法 以环磷酰胺化疗引起大鼠淋巴细胞减少,并建立免疫重建大鼠模型,用活肿瘤疫苗GM-CSF/NUTU-19免疫大鼠模型,收集肿瘤疫苗免疫部位引流淋巴结,制备效应T淋巴细胞(T_E),酶联免疫吸附试验测定T_E分泌IL(白细胞介素)2、IL-4的能力,细胞内细胞因子染色法测定肿瘤特异性T_E的频数,流式细胞仪测定T_E对靶细胞的特异性细胞毒杀伤率.并将T_E过继回输给腹腔荷卵巢癌的大鼠,观察其生存期.结果 化疗-免疫重建-肿瘤疫苗免疫大鼠T_E分泌的IL-2水平增高,为(65.7±4.0)pg/ml,IL-d.分泌水平降低,为(277±49)pg/ml;细胞内细胞因子染色法结果提示,能分泌干扰素γ的CD_4~+;T淋巴细胞频数增高,为(13.0±2.1)%;T_E对靶细胞的杀伤率提高,为(86.5±1.1)%;经化疗-免疫重建-肿瘤疫苗免疫大鼠T_E过继免疫治疗的荷瘤大鼠生存期延长,平均生存时间为(110±16)d.结论 化疗-免疫重建-肿瘤疫苗免疫治疗能使肿瘤特异性T_E频数增加、功能增强,提高肿瘤特异性杀伤能力,有助于改善肿瘤特异性T_E细胞对肿瘤抗原弱刺激的反应性,增强抗肿瘤免疫反应.
目的 探索化療後淋巴細胞減少期行免疫重建及應用GM-CSF基因脩飾的卵巢上皮性癌(卵巢癌)腫瘤疫苗過繼免疫治療方案增彊抗腫瘤免疫反應的機製及效果.方法 以環燐酰胺化療引起大鼠淋巴細胞減少,併建立免疫重建大鼠模型,用活腫瘤疫苗GM-CSF/NUTU-19免疫大鼠模型,收集腫瘤疫苗免疫部位引流淋巴結,製備效應T淋巴細胞(T_E),酶聯免疫吸附試驗測定T_E分泌IL(白細胞介素)2、IL-4的能力,細胞內細胞因子染色法測定腫瘤特異性T_E的頻數,流式細胞儀測定T_E對靶細胞的特異性細胞毒殺傷率.併將T_E過繼迴輸給腹腔荷卵巢癌的大鼠,觀察其生存期.結果 化療-免疫重建-腫瘤疫苗免疫大鼠T_E分泌的IL-2水平增高,為(65.7±4.0)pg/ml,IL-d.分泌水平降低,為(277±49)pg/ml;細胞內細胞因子染色法結果提示,能分泌榦擾素γ的CD_4~+;T淋巴細胞頻數增高,為(13.0±2.1)%;T_E對靶細胞的殺傷率提高,為(86.5±1.1)%;經化療-免疫重建-腫瘤疫苗免疫大鼠T_E過繼免疫治療的荷瘤大鼠生存期延長,平均生存時間為(110±16)d.結論 化療-免疫重建-腫瘤疫苗免疫治療能使腫瘤特異性T_E頻數增加、功能增彊,提高腫瘤特異性殺傷能力,有助于改善腫瘤特異性T_E細胞對腫瘤抗原弱刺激的反應性,增彊抗腫瘤免疫反應.
목적 탐색화료후림파세포감소기행면역중건급응용GM-CSF기인수식적란소상피성암(란소암)종류역묘과계면역치료방안증강항종류면역반응적궤제급효과.방법 이배린선알화료인기대서림파세포감소,병건립면역중건대서모형,용활종류역묘GM-CSF/NUTU-19면역대서모형,수집종류역묘면역부위인류림파결,제비효응T림파세포(T_E),매련면역흡부시험측정T_E분비IL(백세포개소)2、IL-4적능력,세포내세포인자염색법측정종류특이성T_E적빈수,류식세포의측정T_E대파세포적특이성세포독살상솔.병장T_E과계회수급복강하란소암적대서,관찰기생존기.결과 화료-면역중건-종류역묘면역대서T_E분비적IL-2수평증고,위(65.7±4.0)pg/ml,IL-d.분비수평강저,위(277±49)pg/ml;세포내세포인자염색법결과제시,능분비간우소γ적CD_4~+;T림파세포빈수증고,위(13.0±2.1)%;T_E대파세포적살상솔제고,위(86.5±1.1)%;경화료-면역중건-종류역묘면역대서T_E과계면역치료적하류대서생존기연장,평균생존시간위(110±16)d.결론 화료-면역중건-종류역묘면역치료능사종류특이성T_E빈수증가、공능증강,제고종류특이성살상능력,유조우개선종류특이성T_E세포대종류항원약자격적반응성,증강항종류면역반응.
Objective To explore the mechanisms and effects of adoptive immunotherapy with ovarian cancer vaccine modified by GM-CSF gene which was used after immunologic reconstitution during lymphopenia induced by chemotherapy.Methods Lymphopenia was induced by chemotherapy with cyclophosphamide.The immune reconstituted model was built in rats.The tumor vaccine draining lymph nodes were harvested after the ovarian cancer cells NUTU-19 modified by GM-CSF gene were injected.The effector T cells (T_E) were got after being stimulated and amplified.Enzyme-linked immunosorbent assay was used to detect the level of interleukin (IL)-2 and IL-4 secreted by T_E.Intracellular cytokine staining was used to determine frequency of tumor-specific T_E.Fluorescence-activated cell sorting (FACS) was used to detect the special cytotoxicity ofT_E killing target cells.The survival period of rats bearing pre-established abdominal ovariam carcinoma after being adoptively transferred byT_E.was observed.Results Compared with those in control group,the significant higher levels IL-2[(65.7±4.0) pg/ml]and lower levels IL-4 [(277±49) pg/ml]were observed in chemotherapy-immune recunstitution-vaccine immunization group.The amount of CD_4~+ T cells secreting interferon-γ (13.0±2.1)% were also significantly increased.The rate of the special cytotoxicity of killing T cells (86.5±1.1) % was markedly improved.The survival period of rats (110±16) days was increased in chemotherapy-immune reconstitution-vaccine immunization group.Conclusions The combined immunotherapy of chemotherapy-immune reconstitution-tumor vaccine immunotherapy may increase the frequency and function of specific tumor T_E.The specific cytotoxicity is increased and the weak reaction of T_E to tumor is improved,which showed that this therapy can enhance immune reaction.